Kenvue's Shares Rebound Amid Controversy Linked to Trump

Kenvue, the maker of Tylenol, has experienced a notable rebound in its share prices, reflecting renewed investor confidence. This recovery comes despite former President Trump's controversial comments linking Tylenol to autism, which raised concerns but are deemed unlikely to significantly impact the company's stock. The situation underscores the resilience of the healthcare sector amidst political and public discourse.